Learning Objectives
At the conclusion of this activity, participants will be able to:
• Explain the emerging role of chimeric antigen receptor (CAR) T-cell treatment as an option for patients with relapsed/refractory blood cancer
• Discuss treatment plans for patient care
• Explain potential short- and long-term side effects and management
• Identify patients who could potentially be treated with CAR therapy
• Engage patients and caregivers in discussions on CAR T-cell therapies including benefits, risks, and barriers to entry
 
Target Audience 
Hematologists-oncologists, medical oncologists, oncology fellows, pharmacists,  physician assistants, nurse practitioners, nurses, and oncology social workers at the intermediate and advanced level involved in the care of patients with hematologic malignancies.  

Questions/Grievances

For questions, grievances, or assistance with special needs (physical, dietary, etc.) please contact us prior to the program at (914) 821-8420 or email caroline.kornhauser@lls.org.

 

Providers

This activity is jointly provided by The Leukemia & Lymphoma Society & Medical Learning Institute, Inc.

 

Supporters

This activity is supported by educational grants from Celgene Corporation, and Kite, a Gilead Company.

 

Continuing Education Information (See additional Tab)

There is no fee for this educational activity. To receive credit for this CME/CPE/CE activity, complete the pre-assessment, course, post-assessment, and evaluation and return it to the on-site coordinator. Your certificate of credit will be e-mailed to you within 4 weeks. For pharmacists, MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: mycpemonitor.net.